Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for...

Source: Journal of Hematology and Oncology - June 28, 2023 Category: Hematology Authors: Yang Cao, Emanuela C. Marcucci and Lihua E. Budde Tags: Review Source Type: research